SciSparc(SPRC.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
SciSparc
SPRC.US
SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer’s disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufacture SCI-110, palmitoylethanolamide oral tablets and CannAmide in softgel capsule form.
4.838 T
SPRC.USMarket value -Rank by Market Cap -/-

Financial Score

18/01/2026 Update
D
PharmaceuticalsIndustry
Industry Ranking0/186
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-1375.72%E
    • Profit Margin-4294.64%E
    • Gross Margin0.00%E
  • Growth ScoreE
    • Revenue YoY-14.44%E
    • Net Profit YoY-837.30%E
    • Total Assets YoY0.00%C
    • Net Assets YoY-100.00%E
  • Cash ScoreD
    • Cash Flow Margin-2.33%D
    • OCF YoY-14.44%E
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio0.00%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    SciSparc Moves Into Endoscopy With Strategic Patent Deal

    SciSparc Ltd. (NASDAQ:SPRC) has announced a definitive agreement to acquire a portfolio of medical endoscopy patents, aiming to expand into the medical device sector. Following the announcement, SciSparc shares fell by 12.07% to $1.27. The acquisition includes patents related to the MUSE endoscopic system and is expected to enhance commercialization efforts. The deal will involve issuing shares representing about 19.99% of the company's outstanding stock, pending regulatory approvals, with an expected closing date by March 8, 2026.

    benzinga_article·
    US
    SPRC
    +1.90%
    benzinga_article·
    US
    SPRC
    +1.90%

    SciSparc To Buy IP Rights For Endoscopic Systems And Medical Cameras

    SciSparc Ltd. (SPRC) has announced a definitive agreement to acquire patents and intellectual property rights for endoscopic systems and medical cameras from Xylo Technologies Ltd. The company will issue common shares as consideration for the assets. Following the deal's closure, SciSparc plans to commercialize these technologies to enhance market penetration and revenue. In pre-market trading, SPRC shares rose 21.3% to $1.76 on the Nasdaq.

    rttnews·
    US
    SPRC
    +1.90%
    rttnews·
    US
    SPRC
    +1.90%

    SciSparc acquires patents for endoscope market, entering a multi-billion dollar opportunity. Commercialization to start post transaction.

    SciSparc plans to start commercializing the patented technologies right after the completion of the transaction.

    Unusual Whales·
    US
    SPRC
    +1.90%
    Unusual Whales·
    US
    SPRC
    +1.90%

    SciSparc Signs Definitive Agreement to Acquire a Treasury of Patents for the Endoscope Market- Entering Multi-Billion Dollar Opportunity | SPRC Stock News

    SciSparc Ltd. has signed a definitive agreement to acquire a portfolio of patents and intellectual property rights for innovative endoscopic systems, including the MUSE™ system, from Xylo Technologies Ltd. The company plans to commercialize these technologies immediately after the transaction closes on March 8, 2026. SciSparc aims to replicate Xylo's successful commercialization model in Greater China across North America, Europe, and Latin America, targeting the growing GERD device market, projected to reach $3.03 billion by 2030.

    StockTitan·
    US
    SPRC
    +1.90%
    StockTitan·
    US
    SPRC
    +1.90%

    SciSparc Ltd. notified by Nasdaq for failing to meet minimum stockholders' equity requirement. As of June 30, 2025, reported stockholders' equity was approximately $(81,000).

    SciSparc Ltd. has received a Notification Letter from Nasdaq for failing to meet the minimum stockholders' equity requirement for listing on the Nasdaq Capital Market. As of June 30, 2025, the company's stockholders' equity was approximately $(81,000), significantly below the required minimum of $2,500,000. This situation puts SciSparc at risk of losing its Nasdaq listing under Rule 5550(b)(1). The company, which focuses on clinical-stage pharmaceutical developments, must take action to rectify this issue to maintain its listing status.

    Unusual Whales·
    US
    NDAQ
    +0.65%
    US
    SPRC
    +1.90%
    Unusual Whales·
    US
    NDAQ
    +0.65%
    US
    SPRC
    +1.90%
    © 2026 Longbridge｜Disclaimer